Related Experiment Video
Updated: Aug 20, 2026
Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans
Published on: October 5, 2020
Gene expression profiling of tumours derived from rasV12/E1A-transformed mouse embryonic fibroblasts to identify
Sophie Vasseur1, Cédric Malicet, Ezequiel L Calvo
1INSERM U,624, Stress Cellulaire, 163 Avenue de Luminy, Case 915, Parc Scientifique et Technologique de Luminy, 13288 Marseille Cedex 9, France. vasseur@marseille.inserm.fr <vasseur@marseille.inserm.fr>
Background:
In cancer, cellular transformation is followed by tumour development. Knowledge on the mechanisms of transformation, involving activation of proto-oncogenes and inactivation of tumour-suppressor genes has considerably improved whereas tumour development remains poorly understood. An interesting way of gaining information on tumour progression mechanisms would be to identify genes whose expression is altered during tumour formation. We used the Affymetrix-based DNA microarray technology to analyze gene expression profiles of tumours derived from rasV12/E1A-transformed mouse embryo fibroblasts in order to identify the genes that could be involved in tumour development.
Results:
Among the 12,000 genes analyzed in this study, only 489 showed altered expression during tumour development, 213 being up-regulated and 276 down-regulated. The genes differentially expressed are involved in a variety of cellular functions, including control of transcription, regulation of mRNA maturation and processing, regulation of protein translation, activation of interferon-induced genes, intracellular signalling, apoptosis, cell growth, angiogenesis, cytoskeleton, cell-to-cell interaction, extracellular matrix formation, metabolism and production of secretory factors.
Conclusions:
Some of the genes identified in this work, whose expression is altered upon rasV12/E1A transformation of MEFs, could be new cancer therapeutic targets.
Insights
Researchers identified genes with altered expression during tumor development in rasV12/E1A-transformed mouse embryo fibroblasts (MEFs). These genes, involved in various cellular functions, may offer new therapeutic targets for cancer.
Area of Science:
- Oncology
- Molecular Biology
- Gene Expression Profiling
Background:
- Tumor development mechanisms remain poorly understood despite advances in understanding cellular transformation.
- Identifying genes with altered expression during tumor formation is crucial for understanding tumor progression.
- This study focuses on gene expression changes during tumor development in a specific mouse model.
Purpose of the Study:
- To identify genes involved in tumor development by analyzing gene expression profiles.
- To gain insights into the molecular mechanisms underlying tumor progression.
- To discover potential new therapeutic targets for cancer treatment.
Main Methods:
- Utilized Affymetrix-based DNA microarray technology.
- Analyzed gene expression profiles of tumors derived from rasV12/E1A-transformed mouse embryo fibroblasts (MEFs).
- Compared gene expression between transformed and non-transformed cells to identify differentially expressed genes.
Main Results:
- Out of 12,000 genes analyzed, 489 showed altered expression during tumor development.
- 213 genes were up-regulated and 276 genes were down-regulated.
- Differentially expressed genes are implicated in critical cellular functions including transcription, translation, signaling, apoptosis, angiogenesis, and metabolism.
Conclusions:
- The study identified genes with altered expression following rasV12/E1A transformation in MEFs.
- Some of these identified genes represent potential novel therapeutic targets for cancer.
- Further research into these genes could advance cancer treatment strategies.
More Related Videos
10:31The Drosophila Imaginal Disc Tumor Model: Visualization and Quantification of Gene Expression and Tumor Invasiveness Using Genetic Mosaics
Published on: October 6, 2016
09:33Genetic Profiling and Genome-Scale Dropout Screening to Identify Therapeutic Targets in Mouse Models of Malignant Peripheral Nerve Sheath Tumor
Published on: August 25, 2023
